WESTMINSTER, Colo., USA  December 4, 2012–Surefire Medical, Inc., the developer of innovative high-efficiency, reflux-reducing infusion systems for the interventional radiology and interventional oncology markets, today announced the first successful case using the Surefire Infusion System in Europe. The procedure was performed by Tobias Jakobs, M.D. of Krankenhaus Barmherzige Brueder in Munich, Germany.

The Surefire Infusion System has a unique expandable tip that is designed to minimize reflux and improve embolization efficiency during infusion procedures.  The tip expands during reverse blood flow, reducing reflux or backflow, assuring that the full dose of diagnostic or therapeutic agent reaches only the intended tumor site with little or no damage to healthy tissue.

“Compared to a standard microcatheter, using the Surefire Infusion System increases radiologists’ confidence to deliver therapeutic agents precisely to the target area in both radioembolic and chemoembolic procedures without causing reflux into vessels leading into the GI tract,” said Dr. Jakobs. “Because of the Surefire anti-reflux technology, physicians may also opt to coil less during procedures in the future.”

Dr. Jakobs, assisted by Johannes Rieger, M.D., performed a diagnostic procedure with the Surefire device as well as a drug-eluting bead (DEB) procedure.

Surefire Medical received CE Mark approval for its Surefire Infusion System in June 2012.  The device is available in Germany from Angiopro GmbH.   Products are also available in a growing number of countries worldwide.  Future growth of Surefire Medical will include other European markets as well as Asia, South America and the Mid-East.

“The positive results with our first European case mark a significant step in achieving our growth goals worldwide,” said Jim Chomas, CEO of Surefire Medical. “We continue to gain momentum in the U.S. and internationally with innovative, more effective products for the interventional radiology market that not only improve patients’ lives but also provide new treatment options for patients previously thought untreatable.”


Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.